FAQs
Pre-eclampsia announcement (22nd April, 2008)
1. Now you have completed the phase 2 study, does this mean that the product will be on the market soon?
This initial study in pregnant women (23-34 weeks) met one of its primary objectives. However further analysis of the data needs to be completed before we understand what direction this programme will take. The product is at an early stage of its development and if it is going to be developed further it will need to go through larger studies.These studies will take several years.
2. If this product is not available, what other treatments can be used?
For many years, doctors have managed the symptoms of pre-eclampsia with existing drugs, such as anti-hypertensives to lower blood pressure and anti-convulsants, but there is currently no treatment which tackles the underlying cause of the disease. Protherics advises pregnant women to consult with their doctor if feeling unwell.
3. Where can I get further information on the study?
Once the full DEEP results are available, Protherics will publish them on the website. The full study design is available on www.clintrials.gov.
4. Where can I get further information on the disease area?
You can obtain further information on pre-eclampsia from your physician or one of the patient support groups, such as the ‘Pre-eclampsia Foundation’ in the US and ‘Action on Pre-eclampsia’ in the UK.
5. How can I enter into a clinical study?
We are still evaluating the phase 2 study results and, as yet, no decisions have been made about when and where future clinical studies will be undertaken. Updated information will be available on our web site later in the year.
6. Can my doctor give me Digibind® if I have pre-eclampsia?
Digibind® is only licensed for treating digoxin toxicity and therefore use of this drug in pre-eclampsia is very limited. Please consult with your treating physician.
General FAQs
1. When was Protherics formed?
Protherics was formed in September 1999 through the merger of Proteus International PLC and Therapeutic Antibodies Inc.
2. What is the ticker symbol for Protherics and on what exchange do the shares trade?
Please see our Shareholder Information section
3. How many shares does Protherics' have in issue?
Please see our Shareholder Information section
4. How can I get a copy of Protherics' Annual Report?
You can view a copy of the latest Financial Report by clicking on this link or if you require it in hard copy you can request it from the Financial Times Annual Reports Service.
5. When does Protherics' report its financial results?
The Protherics financial year end is the 31st March and results are usually reported at the beginning of June. The half year end is the 30th September and the interim statement is usually published at the beginning of December.
6. Who do I contact if I have a query about my share certificate?
Please contact our registrars:
Capita Registrars
Northern House
Woodsome Park
Fenay Bridge
Huddersfield West
Yorkshire HD8 0LA UK
Email: shareholder.services@capitaregistrars.com
Tel: 0870 162 3131 (if calling from overseas +44 208 639 2300)
Fax: 0208 639 2342 (if calling from overseas +44 208 639 2342)
7. How can I buy and sell Protherics' shares?
You can deal in Protherics' shares through any Stockbroker who trades shares in companies listed on the London Stock Exchange.
8. When can I convert my Enact loan note?
The loan note can be converted from 19 December 2004
9. If I have an old share certificate in the name of Proteus International PLC, is it still valid?
Your share certificate is still valid and will be accepted in the normal way.
Please contact our Investor Relations team if you have any further questions